You just read:

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)

News provided by

Janssen Biotech, Inc.

Oct 01, 2014, 15:35 ET